

IL13

Research Grade Anrukinzumab

Catalog No.	DHE07706A DHE07706B	Quantity:	100 µg 1.0 mg
Alternate Names:	Interleukin-13, IL-13, IMA-638		
Description:	Anrukinzumab is a humanized monoclonal antibody that binds to IL-13 and inhibits attachment of IL-13 to IL-4R α , thus interrupting IL-13 signaling. It was developed for the treatment of asthma and ulcerative colitis.		
Concentration:	1.0 mg/ml, lot specific		
UniProt ID (target):	P35225		
Source:	XtenCHO cell line		
Isotype:	Human IgG1 kappa		
INN:	Anrukinzumab		
Specificity:	Human IL-13		
Endotoxin:	≤ 0.01 EU/ μ g by LAL analysis		
Formulation:	0.01M PBS, pH 7.4		
Purification:	Protein A/G affinity chromatography		
Purity:	> 95% as determined by SDS-PAGE		
Storage & Stability:	Recommended storage, undiluted at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.